Advertisement
Review article| Volume 298, ISSUE 1-2, P11-16, November 15, 2010

Download started.

Ok

The pre-requisite of a second-generation glioma PET biomarker

  • Katalin Borbely
    Correspondence
    Corresponding author. Tel.: +36 1 224 8600; fax: +36 1 224 8720.
    Affiliations
    PET/CT Amb, National Institute of Oncology, 1122 Budapest, Rath Gyorgy 7-9, Hungary
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +1 434 243 9312; fax: +1 434 982 5753.
    Max Wintermark
    Footnotes
    1 Tel.: +1 434 243 9312; fax: +1 434 982 5753.
    Affiliations
    Neuroradiology Division, University of Virginia, Department of Radiology, Charlottesville, VA, USA
    Search for articles by this author
  • Author Footnotes
    2 Tel.: +36 1 2512999; fax: +36 1 2515678.
    Janos Martos
    Footnotes
    2 Tel.: +36 1 2512999; fax: +36 1 2515678.
    Affiliations
    Department of Neuroradiology, National Institute of Neurosurgery, 1145 Budapest, Amerikai 45, Hungary
    Search for articles by this author
  • Author Footnotes
    2 Tel.: +36 1 2512999; fax: +36 1 2515678.
    Imre Fedorcsak
    Footnotes
    2 Tel.: +36 1 2512999; fax: +36 1 2515678.
    Affiliations
    Department of Neurosurgery, National Institute of Neurosurgery, 1145 Budapest, Amerikai 45, Hungary
    Search for articles by this author
  • Author Footnotes
    3 Tel.: +36 52 411 717; fax: +36 52 419 418.
    Laszlo Bognar
    Footnotes
    3 Tel.: +36 52 411 717; fax: +36 52 419 418.
    Affiliations
    Department of Neurosurgery, Debrecen University Medical Faculties, 4032 Debrecen, Nagyerdei krt 98, Hungary
    Search for articles by this author
  • Author Footnotes
    4 Tel.: +36 1 224 8600; fax: +36 1 8667.
    Miklos Kasler
    Footnotes
    4 Tel.: +36 1 224 8600; fax: +36 1 8667.
    Affiliations
    National Institute of Oncology, 1122 Budapest, Rath Gyorgy 7-9, Hungary
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +1 434 243 9312; fax: +1 434 982 5753.
    2 Tel.: +36 1 2512999; fax: +36 1 2515678.
    3 Tel.: +36 52 411 717; fax: +36 52 419 418.
    4 Tel.: +36 1 224 8600; fax: +36 1 8667.
Published:August 26, 2010DOI:https://doi.org/10.1016/j.jns.2010.07.024
The pre-requisite of a second-generation glioma PET biomarker
Previous ArticlePerspectives of Kennedy's disease
Next ArticleNeurology education in Latin America and the World Federation of Neurology

      Abstract

      Since the introduction of FDG into the field of molecular imaging with positron emission tomography (PET) more than three decades ago, FDG has been the tracer of choice for oncology PET imaging. Despite the relative disadvantages of FDG and the relative benefits of its challengers, FDG remains the most commonly used glioma tracer nowadays. The present article surveys the expectations of the field and gives a concise summary of recent developments; including the issues pertaining to the continued search for an optimal second-generation PET biomarker for glioma.

      Mini-abstract

      The present article gives a concise summary of recent developments; including the issues pertaining to the continued search for an optimal PET biomarker for glioma.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Halldin C.
        • Gulyas B.
        • Farde L.
        PET studies with carbon-11 radioligands in neuropsychological drug development.
        Current Radiopharm Design. 2001; : 1907-1929
        View in Article
        • Verbruggen A.
        • Coenen H.H.
        • Deverre J.R.
        • Guilloteau D.
        • Langstrom B.
        • Salvadori P.A.
        • et al.
        Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU.
        Eur J Nucl Med Mol Imaging. 2008; Nov;35: 2144-2151
        View in Article
        • Yamamoto Y.
        • Nishiyama Y.
        • Kimura N.
        • Kameyama R.
        • Kawai N.
        • Hatakeyama T.
        • et al.
        11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET.
        Mol Imaging Biol. Sep 2008; 10 (Epub 2008 Jun 10): 281-287
        View in Article
        • De Witte O.
        • Oulad Ben Taib N.
        • Branle F.
        • Rorive S.
        • Brotchi J.
        • Goldman S.
        • et al.
        Contribution of PET to the management of patients with low-grade glioma.
        Neurochirurgie. Sep 2004; 50: 468-473
        View in Article
        • Kaschten B.
        • Stevenaert A.
        • Sadzot B.
        • Deprez M.
        • Degueldre C.
        • Del Fiore G.
        • et al.
        Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
        J Nucl Med. 1998 May; 39: 778-785
        View in Article
        • Borbély K.
        • Nyáry I.
        • Tóth M.
        • Ericson K.
        • Gulyáset B.
        Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
        J Neurol Sci. Jul 15 2006; 246 (Epub 2006 Mar 6): 85-94
        View in Article
        • Pötzi C.
        • Becherer A.
        • Marosi C.
        • Karanikas G.
        • Szabo M.
        • Dudczak R.
        • et al.
        [11C]methionine and [18F]fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.
        J Neurooncol. Sep 2007; 84 (Epub 2007 May 11): 305-314
        View in Article
        • Kato T.
        • Shinoda J.
        • Nakayama N.
        • Miwa K.
        • Okumura A.
        • Yano H.
        • et al.
        Metabolic assessment of gliomas using [11C]-methionine, [18F]-fluorodeoxyglucose, and [11C]-choline positron-emission tomography.
        Am J Neuroradiol. 2008; 29: 1176-1182
        View in Article
        • Yamaguchi S.
        • Terasaka S.
        • Kobayashi H.
        • Shiga T.
        • Usui R.
        • Hirata K.
        • et al.
        Indolent dorsal midbrain tumor: new findings based on positron emission tomography.
        J Neurosurg Pediatr. Apr 2009; 3: 270-275
        View in Article
        • Gulyás B.
        • Nyáry I.
        • Borbély K.
        FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues.
        Nat Clin Pract Neurol. Sep 2008; 4 (Epub 2008 Jul 15): 470-471
        View in Article
        • Kincaid P.K.
        • El-Saden S.M.
        • Park S.H.
        • Goy B.W.
        Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT.
        Am J Neuroradiol. 1998; 19: 801-806
        View in Article
        • Gómez-Río M.
        • Rodríguez-Fernández A.
        • Ramos-Font C.
        • López-Ramírez E.
        • Llamas-Elvira J.M.
        Diagnostic accuracy of 201-Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence.
        Eur J Nucl Med Mol Imaging. May 2008; 35 (Epub 2008 Jan 3): 966-975
        View in Article
        • Vlassenko A.G.
        • Thiessen B.
        • Beattie B.J.
        • Malkin M.G.
        • Blasberg R.G.
        Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
        J Neurooncol. 2000; 46: 249-259
        View in Article
        • Huang Z.
        • Zuo C.
        • Guan Y.
        • Zhang Z.
        • Liu P.
        • Xue F.
        • et al.
        Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours.
        Nucl Med Commun. Apr 2008; 29: 354-358
        View in Article
        • Wester H.J.
        • Herz M.
        • Weber W.
        • Heiss P.
        • Senekowitsch-Schmidtke R.
        • Schwaiger M.
        • et al.
        Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumor imaging.
        J Nucl Med. Jan 1999; 40: 205-212
        View in Article
        • Wang H.E.
        • Wu S.Y.
        • Chang C.W.
        • Liu R.S.
        • Hwang L.C.
        • Lee T.W.
        • et al.
        Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
        Nucl Med Biol. May 2005; 32: 367-375
        View in Article
        • Pauleit D.
        • Stoffels G.
        • Bachofner A.
        • Floeth F.W.
        • Sabel M.
        • Herzog H.
        • et al.
        Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
        Nucl Med Biol. Oct 2009; 36 (Epub 2009 Jul 29): 779-787
        View in Article
        • Weber D.C.
        • Zilli T.
        • Buchegger F.
        • Casanova N.
        • Haller G.
        • Rouzaud M.
        • et al.
        (18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma.
        Radiat Oncol. Dec 2008; 24: 44
        View in Article
        • Vees H.
        • Senthamizhchelvan S.
        • Miralbell R.
        • Weber D.C.
        • Ratib O.
        • Zaidi H.
        Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients.
        Eur J Nucl Med Mol Imaging. Feb 2009; 36 (Epub 2008 Sep 26): 182-193
        View in Article
        • Lau E.W.
        • Drummond K.J.
        • Ware R.E.
        • Drummond E.
        • Hogg A.
        • Ryan G.
        • et al.
        Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour.
        J Clin Neurosci. Jan 2010; 17 (Epub 2009 Dec 9): 43-49
        View in Article
        • Langen K.J.
        • Hamacher K.
        • Weckesser M.
        • Floeth F.
        • Stoffels G.
        • Bauer D.
        • et al.
        O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications.
        Nucl Med Biol. Apr 2006; 33: 287-294
        View in Article
        • Thiele F.
        • Ehmer J.
        • Piroth M.D.
        • Eble M.J.
        • Coenen H.H.
        • Kaiser H.J.
        • et al.
        The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma.
        Phys Med Biol. Sep 21 2009; 54 (Epub 2009 Aug 28): 5525-5539
        View in Article
        • Pöpperl G.
        • Kreth F.W.
        • Mehrkens J.H.
        • Herms J.
        • Seelos K.
        • Koch W.
        • et al.
        FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.
        Eur J Nucl Med Mol Imaging. Dec 2007; 34 (Epub 2007 Sep 1): 1933-1942
        View in Article
        • Floeth F.W.
        • Pauleit D.
        • Sabel M.
        • Reifenberger G.
        • Stoffels G.
        • Stummer W.
        • et al.
        18F-FET PET differentiation of ring-enhancing brain lesions.
        J Nucl Med. May 2006; 47: 776-782
        View in Article
        • Spaeth N.
        • Wyss M.T.
        • Pahnke J.
        • Biollaz G.
        • Lutz A.
        • Goepfert K.
        • et al.
        Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-l: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.
        Eur J Nucl Med Mol Imaging. Jun 2006; 33 (Epub 2006 Mar 15): 673-682
        View in Article
        • Lee T.S.
        • Ahn S.H.
        • Moon B.S.
        • Chun K.S.
        • Kang J.H.
        • Cheon G.J.
        • et al.
        Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats.
        Nucl Med Biol. Aug 2009; 36: 681-686
        View in Article
        • Wyss M.
        • Hofer S.
        • Bruehlmeier M.
        • Hefti M.
        • Uhlmann C.
        • Bärtschi E.
        • et al.
        Early metabolic responses in temozolomide treated low-grade glioma patients.
        J Neurooncol. Oct 2009; 95 (Epub 2009 Apr 18): 87-93
        View in Article
        • Wyss M.T.
        • Spaeth N.
        • Biollaz G.
        • Pahnke J.
        • Alessi P.
        • Trachsel E.
        • et al.
        Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis.
        J Nucl Med. Apr 2007; 48: 608-614
        View in Article
        • Stockhammer F.
        • von Deimling A.
        • Synowitz M.
        • Blechschmidt C.
        • van Landeghem F.K.
        Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II.
        J Mol Histol. Oct 2008; 39 (Epub 2008 Aug 26): 553-560
        View in Article
        • Piroth M.D.
        • Pinkawa M.
        • Holy R.
        • Stoffels G.
        • Demirel C.
        • Attieh C.
        • et al.
        Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme—a dosimetric comparison.
        Radiat Oncol. Nov 2009; 23: 57
        View in Article
        • Weber D.C.
        • Casanova N.
        • Zilli T.
        • Buchegger F.
        • Rouzaud M.
        • Nouet P.
        • et al.
        Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study.
        Radiother Oncol. Dec 2009; 93 (Epub 2009 Sep 24): 586-592
        View in Article
        • Stadlbauer A.
        • Prante O.
        • Nimsky C.
        • Salomonowitz E.
        • Buchfelder M.
        • Kuwert T.
        • et al.
        Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-l-tyrosine PET and proton magnetic resonance spectroscopic imaging.
        J Nucl Med. May 2008; 49 (Epub 2008 Apr 15): 721-729
        View in Article
        • Stadlbauer A.
        • Pölking E.
        • Prante O.
        • Nimsky C.
        • Buchfelder M.
        • Kuwert T.
        • et al.
        Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of (18)F-fluoroethyl-l: -tyrosine PET and magnetic resonance diffusion tensor imaging.
        Acta Neurochir (Wien). Sep 2009; 151 (Epub 2009 May 26): 1061-1069
        View in Article
        • Rachinger W.
        • Goetz C.
        • Pöpperl G.
        • Gildehaus F.J.
        • Kreth F.W.
        • Holtmannspötter M.
        • et al.
        Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.
        Neurosurgery. Sep 2005; 57 (discussion 505-11): 505-511
        View in Article
        • Messing-Jünger A.M.
        • Floeth F.W.
        • Pauleit D.
        • Reifenberger G.
        • Willing R.
        • Gärtner J.
        • et al.
        Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas.
        Childs Nerv Syst. Aug 2002; 18 (Epub 2002 Jul 26): 445-449
        View in Article
        • Floeth F.W.
        • Pauleit D.
        • Wittsack H.J.
        • Langen K.J.
        • Reifenberger G.
        • Hamacher K.
        • et al.
        Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopy.
        J Neurosurg. Feb 2005; 102: 318-327
        View in Article
        • Floeth F.W.
        • Sabel M.
        • Stoffels G.
        • Pauleit D.
        • Hamacher K.
        • Steiger H.J.
        • et al.
        Prognostic value of 18F-fluoroethyl-l-tyrosine PET and MRI in small nonspecific incidental brain lesions.
        J Nucl Med. May 2008; 49 (Epub 2008 Apr 15): 730-737
        View in Article
        • Stockhammer F.
        • Misch M.
        • Horn P.
        • Koch A.
        • Fonyuy N.
        • Plotkin M.
        Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas.
        Acta Neurochir (Wien). Nov 2009; 151 (Epub 2009 Jul 29): 1377-1383
        View in Article
        • Pöpperl G.
        • Götz C.
        • Rachinger W.
        • Gildehaus F.J.
        • Tonn J.C.
        • Tatsch K.
        Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma.
        Eur J Nucl Med Mol Imaging. Nov 2004; 31 (Epub 2004 Jul 10): 1464-1470
        View in Article
        • Pauleit D.
        • Floeth F.
        • Hamacher K.
        • Riemenschneider M.J.
        • Reifenberger G.
        • Müller H.W.
        • et al.
        O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.
        Brain. Mar 2005; 128 (Epub 2005 Feb 2): 678-687
        View in Article
        • Fedorova O.S.
        • Kuznetsova O.F.
        • Shatik S.V.
        • Stepanova M.A.
        • IuN Belokon'
        • Maleev V.I.
        • et al.
        (18)F-labeled tyrosine derivatives: synthesis and experimental studies on accumulation in tumors and abscesses.
        Bioorg Khim. May-Jun 2009; 35: 334-343
        View in Article
        • Burchardt C.
        • Riss P.J.
        • Zoller F.
        • Maschauer S.
        • Prante O.
        • Kuwert T.
        • et al.
        (68)Ga]Ga-DO(2)A-(OBu-l-tyr)(2): synthesis, (68)Ga-radiolabeling and in vitro studies of a novel (68)Ga-DO(2)A-tyrosine conjugate as potential tumor tracer for PET.
        Bioorg Med Chem Lett. Jul 1 2009; 19 (Epub 2009 May 7): 3498-3501
        View in Article
        • Pauleit D.
        • Floeth F.
        • Tellmann L.
        • Hamacher K.
        • Hautzel H.
        • Müller H.W.
        • et al.
        Comparison of O-(2-18F-fluoroethyl)-l-tyrosine PET and 3-123I-iodo-alpha-methyl-l-tyrosine SPECT in brain tumors.
        J Nucl Med. Mar 2004; 45: 374-381
        View in Article
        • van Waarde A.
        • Cobben D.C.
        • Suurmeijer A.J.
        • Maas B.
        • Vaalburg W.
        • de Vries E.F.
        • et al.
        Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
        J Nucl Med. Apr 2004; 45: 695-700
        View in Article
        • Jacobs A.H.
        • Thomas A.
        • Kracht L.W.
        • Li H.
        • Dittmar C.
        • Garlip G.
        • et al.
        18F-fluoro-l-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
        J Nucl Med. Dec 2005; 46: 1948-1958
        View in Article
        • Chen W.
        • Cloughesy T.
        • Kamdar N.
        • Satyamurthy N.
        • Bergsneider M.
        • Liau L.
        • et al.
        Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
        J Nucl Med. Jun 2005; 46: 945-952
        View in Article
        • Yamamoto Y.
        • Wong T.Z.
        • Turkington T.G.
        • Hawk T.C.
        • Reardon D.A.
        • Coleman R.E.
        3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging.
        Mol Imaging Biol. Nov-Dec 2006; 8: 340-347
        View in Article
        • Hlobilkova A.
        • Ehrmann J.
        • Knizetova P.
        • Krejci V.
        • Kalita O.
        • Kolar Z.
        Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression.
        Neoplasma. 2009; 56: 284-290
        View in Article
        • Bradbury M.S.
        • Hambardzumyan D.
        • Zanzonico P.B.
        • Schwartz J.
        • Cai S.
        • Burnazi E.M.
        • et al.
        Dynamic small-animal PET imaging of tumor proliferation with 3′-deoxy-3′-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
        J Nucl Med. Mar 2008; 49 (Epub 2008 Feb 20): 422-429
        View in Article
        • Price S.J.
        • Fryer T.D.
        • Cleij M.C.
        • Dean A.F.
        • Joseph J.
        • Salvador R.
        • et al.
        Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study.
        Clin Radiol. Jan 2009; 64 (Epub 2008 Sep 4): 52-63
        View in Article
        • Chen W.
        • Delaloye S.
        • Silverman D.H.
        • Geist C.
        • Czernin J.
        • Sayre J.
        • et al.
        Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
        J Clin Oncol. Oct 20 2007; 25: 4714-4721
        View in Article
        • Backes H.
        • Ullrich R.
        • Neumaier B.
        • Kracht L.
        • Wienhard K.
        • Jacobs A.H.
        Noninvasive quantification of (18)F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma.
        Eur J Nucl Med Mol Imaging. Aug 12 2009; ([Epub ahead of print] PMID: 19672593)
        View in Article
        • Ullrich R.T.
        • Kracht L.W.
        • Jacobs A.H.
        Neuroimaging in patients with gliomas.
        Semin Neurol. Sep 2008; 28 (Epub 2008 Oct 8): 484-494
        View in Article
        • Wei L.H.
        • Su H.
        • Hildebrandt I.J.
        • Phelps M.E.
        • Czernin J.
        • Weber W.A.
        Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
        Clin Cancer Res. Jun 1 2008; 14: 3416-3426
        View in Article
        • Muzi M.
        • Spence A.M.
        • O'Sullivan F.
        • Mankoff D.A.
        • Wells J.M.
        • Grierson J.R.
        • et al.
        Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas.
        J Nucl Med. Oct 2006; 47: 1612-1621
        View in Article
        • van Waarde A.
        • Elsinga P.H.
        Proliferation markers for the differential diagnosis of tumor and inflammation.
        Curr Pharm Des. 2008; 14: 3326-3339
        View in Article
        • Hatakeyama T.
        • Kawai N.
        • Nishiyama Y.
        • Yamamoto Y.
        • Sasakawa Y.
        • Ichikawa T.
        • et al.
        11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
        Eur J Nucl Med Mol Imaging. Nov 2008; 35 (Epub 2008 Jun 10): 2009-2017
        View in Article
        • Kawai N.
        • Kagawa M.
        • Miyake K.
        • Nishiyama Y.
        • Yamamoto Y.
        • Shiraishi H.
        • et al.
        Use of 11F-fluorothymidine positron emission tomography in brain tumor.
        No Shinkei Geka. Jul 2009; 37: 657-664
        View in Article
        • Luyten P.R.
        • Marien A.J.
        • Heindel W.
        • van Gerwen P.H.
        • Herholz K.
        • den Hollander J.A.
        • et al.
        Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET.
        Radiology. Sep 1990; 176: 791-799
        View in Article
        • Alger J.R.
        • Frank J.A.
        • Bizzi A.
        • Fulham M.J.
        • DeSouza B.X.
        • Duhaney M.O.
        • et al.
        Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET.
        Radiology. Dec 1990; 177: 633-641
        View in Article
        • Anderson J.H.
        • Strandberg J.D.
        • Wong D.F.
        • Conti P.S.
        • Barker P.B.
        • Blackband S.J.
        • et al.
        Multimodality correlative study of canine brain tumors. Proton magnetic resonance spectroscopy, positron emission tomography, and histology.
        Invest Radiol. Jun 1994; 29: 597-605
        View in Article
        • Shinoura N.
        • Nishijima M.
        • Hara T.
        • Haisa T.
        • Yamamoto H.
        • Fujii K.
        • et al.
        Brain tumors: detection with C-11 choline PET.
        Radiology. Feb 1997; 202: 497-503
        View in Article
        • Vanpouille C.
        • Le Jeune N.
        • Kryza D.
        • Clotagatide A.
        • Janier M.
        • Dubois F.
        • et al.
        Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.
        Eur J Nucl Med Mol Imaging. Aug 2009; 36 (Epub 2009 Mar 20): 1256-1264
        View in Article
        • Utriainen M.
        • Komu M.
        • Vuorinen V.
        • Lehikoinen P.
        • Sonninen P.
        • Kurki T.
        • et al.
        Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS.
        J Neurooncol. May 2003; 62: 329-338
        View in Article
        • van Waarde A.
        • Jager P.L.
        • Ishiwata K.
        • Dierckx R.A.
        • Elsinga P.H.
        Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation.
        J Nucl Med. Jan 2006; 47: 150-154
        View in Article
        • Hara T.
        • Kosaka N.
        • Kishi H.
        PET imaging of prostate cancer using carbon-11-choline.
        J Nucl Med. Jun 1998; 39: 990-995
        View in Article
        • Kotzerke J.
        • Prang J.
        • Neumaier B.
        • Volkmer B.
        • Guhlmann A.
        • Kleinschmidt K.
        • et al.
        Experience with carbon-11 choline positron emission tomography in prostate carcinoma.
        Eur J Nucl Med. Sep 2000; 27: 1415-1419
        View in Article
        • Mathews D.
        • Oz O.K.
        Positron emission tomography in prostate and renal cell carcinoma.
        Curr Opin Urol. Sep 2002; 12: 381-385
        View in Article
        • Bouchelouche K.
        • Capala J.
        • Oehr P.
        Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer.
        Curr Opin Oncol. Sep 2009; 21: 469-474
        View in Article
        • Jerabek P.A.
        • Patrick T.B.
        • Kilbourn M.R.
        • Dischino D.D.
        • Welch M.J.
        Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue.
        Int J Rad Appl Instrum A. 1986; 37: 599-605
        View in Article
        • Rasey J.S.
        • Grunbaum Z.
        • Magee S.
        • Nelson N.J.
        • Olive P.L.
        • Durand R.E.
        • et al.
        Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.
        Radiat Res. Aug 1987; 111: 292-304
        View in Article
        • Rasey J.S.
        • Koh W.J.
        • Grierson J.R.
        • Grunbaum Z.
        • Krohn K.A.
        Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia.
        Int J Radiat Oncol Biol Phys. Nov 1989; 17: 985-991
        View in Article
        • Casciari J.J.
        • Rasey J.S.
        Determination of the radiobiologically hypoxic fraction in multicellular spheroids from data on the uptake of [3H]fluoromisonidazole.
        Radiat Res. Jan 1995; 141: 28-36
        View in Article
        • Valk P.E.
        • Mathis C.A.
        • Prados M.D.
        • Gilbert J.C.
        • Budinger T.F.
        Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
        J Nucl Med. Dec 1992; 33: 2133-2137
        View in Article
        • Rasey J.S.
        • Casciari J.J.
        • Hofstrand P.D.
        • Muzi M.
        • Graham M.M.
        • Chin L.K.
        Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole.
        Radiat Res. 2000; 153: 84-92
        View in Article
        • Tochon-Danguy H.J.
        • Sachinidis J.I.
        • Chan F.
        • Chan J.G.
        • Hall C.
        • Cher L.
        • et al.
        Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high-grade glioma using [18F]fluoromisonidazole (FMISO).
        Nucl Med Biol. Feb 2002; 29: 191-197
        View in Article
        • Cher L.M.
        • Murone C.
        • Lawrentschuk N.
        • Ramdave S.
        • Papenfuss A.
        • Hannah A.
        • et al.
        Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
        J Nucl Med. Mar 2006; 47: 410-418
        View in Article
        • Swanson K.R.
        • Chakraborty G.
        • Wang C.H.
        • Rockne R.
        • Harpold H.L.
        • Muzi M.
        • et al.
        Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
        J Nucl Med. Jan 2009; 50 (Epub 2008 Dec 17): 36-44
        View in Article
        • Szeto M.D.
        • Chakraborty G.
        • Hadley J.
        • Rockne R.
        • Muzi M.
        • Alvord Jr., E.C.
        • et al.
        Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
        Cancer Res. May 15 2009; 69 (Epub 2009 Apr 14): 4502-4509
        View in Article
        • Huchet A.
        • Fernandez P.
        • Allard M.
        • Belkacémi Y.
        • Maire J.P.
        • Trouette R.
        • et al.
        Molecular imaging of tumour hypoxia.
        Cancer Radiothér. Dec 2009; 13 (Epub 2009 Oct 23): 747-757
        View in Article
        • Spence A.M.
        • Muzi M.
        • Swanson K.R.
        • O'Sullivan F.
        • Rockhill J.K.
        • Rajendran J.G.
        • et al.
        Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.
        Clin Cancer Res. May 1 2008; 14: 2623-2630
        View in Article
        • Buxton D.B.
        • Schwaiger M.
        • Nguyen A.
        • Phelps M.E.
        • Schelbert H.R.
        Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux.
        Circ Res. Sep 1988; 63: 628-634
        View in Article
        • Armbrecht J.J.
        • Buxton D.B.
        • Brunken R.C.
        • Phelps M.E.
        • Schelbert H.R.
        Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography.
        Circulation. Oct 1989; 80: 863-872
        View in Article
        • Brown M.A.
        • Myears D.W.
        • Bergmann S.R.
        Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization.
        J Nucl Med. Feb 1989; 30: 187-193
        View in Article
        • Henes C.G.
        • Bergmann S.R.
        • Walsh M.N.
        • Sobel B.E.
        • Geltman E.M.
        Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate.
        J Nucl Med. Sep 1989; 30: 1489-1499
        View in Article
        • Jonson S.D.
        • Welch M.J.
        Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids.
        Nucl Med Biol. 2002 Feb; 29: 211-216
        View in Article
        • Shreve P.
        • Chiao P.C.
        • Humes H.D.
        • Schwaiger M.
        • Gross M.D.
        Carbon-11-acetate PET imaging in renal disease.
        J Nucl Med. Sep 1995; 36: 1595-1601
        View in Article
        • Shreve P.D.
        • Gross M.D.
        Imaging of the pancreas and related diseases with PET carbon-11-acetate.
        J Nucl Med. Aug 1997; 38: 1305-1310
        View in Article
        • Oyama N.
        • Akino H.
        • Kanamaru H.
        • Suzuki Y.
        • Muramoto S.
        • Yonekura Y.
        • et al.
        11C-acetate PET imaging of prostate cancer.
        J Nucl Med. Feb 2002; 43: 181-186
        View in Article
        • Ho C.L.
        • Yu S.C.
        • Yeung D.W.
        11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
        J Nucl Med. Feb 2003; 44: 213-221
        View in Article
        • Tsuchida T.
        • Takeuchi H.
        • Okazawa H.
        • Tsujikawa T.
        • Fujibayashi Y.
        Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET.
        Nucl Med Biol. Feb 2008; 35: 171-176
        View in Article
        • Marik J.
        • Ogasawara A.
        • Martin-McNulty B.
        • Ross J.
        • Flores J.E.
        • Gill H.S.
        • et al.
        PET of glial metabolism using 2-18F-fluoroacetate.
        J Nucl Med. Jun 2009; 50 (Epub 2009 May 14): 982-990
        View in Article
        • Heiss W.D.
        • Wienhard K.
        • Wagner R.
        • Lanfermann H.
        • Thiel A.
        • Herholz K.
        • et al.
        F-Dopa as an amino acid tracer to detect brain tumors.
        J Nucl Med. Jul 1996; 37: 1180-1182
        View in Article
        • Alheit H.
        • Oehme L.
        • Winkler C.
        • Füchtner F.
        • Hoepping A.
        • Grabowski J.
        • et al.
        Radiation treatment planning in brain tumours: potential impact of 3-O-methyl-6-[(18)F]fluoro-l-DOPA and PET.
        Nuklearmedizin. 2008; 47: 200-204
        View in Article
        • Ledezma C.J.
        • Chen W.
        • Sai V.
        • Freitas B.
        • Cloughesy T.
        • Czernin J.
        • et al.
        18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.
        Eur J Radiol. Aug 2009; 71 (Epub 2008 May 29): 242-248
        View in Article
        • Peng F.
        • Juhasz C.
        • Bhambhani K.
        • Wu D.
        • Chugani D.C.
        • Chugani H.T.
        Assessment of progression and treatment response of optic pathway glioma with positron emission tomography using alpha-[(11)C]methyl-l-tryptophan.
        Mol Imaging Biol. May-Jun 2007; 9: 106-109
        View in Article
        • Schnell O.
        • Krebs B.
        • Carlsen J.
        • Miederer I.
        • Goetz C.
        • Goldbrunner R.H.
        • et al.
        Imaging of integrin {alpha}v{beta}3 expression in patients with malignant glioma by [18F]galacto-RGD positron emission tomography.
        Neuro Oncol. Dec 2009; 11: 861-870
        View in Article
        • Ogawa T.
        • Miura S.
        • Murakami M.
        • Iida H.
        • Hatazawa J.
        • Inugami A.
        • et al.
        Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine.
        Eur J Nucl Med. Aug 1996; 23: 889-895
        View in Article
        • van Waarde A.
        • Shiba K.
        • de Jong J.R.
        • Ishiwata K.
        • Dierckx R.A.
        • Elsinga P.H.
        Rapid reduction of sigma1-receptor binding and 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin.
        J Nucl Med. Aug 2007; 48 (Epub 2007 Jul 13): 1320-1326
        View in Article
        • Cai W.
        • Chen K.
        • Mohamedali K.A.
        • Cao Q.
        • Gambhir S.S.
        • Rosenblum M.G.
        • et al.
        PET of vascular endothelial growth factor receptor expression.
        J Nucl Med. Dec 2006; 47: 2048-2056
        View in Article
        • Hsu A.R.
        • Cai W.
        • Veeravagu A.
        • Mohamedali K.A.
        • Chen K.
        • Kim S.
        • et al.
        Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
        J Nucl Med. Mar 2007; 48: 445-454
        View in Article
        • Chen K.
        • Cai W.
        • Li Z.B.
        • Wang H.
        • Chen X.
        Quantitative PET imaging of VEGF receptor expression.
        Mol Imaging Biol. Jan-Feb 2009; 11 (Epub 2008 Sep 11): 15-22
        View in Article
        • Chae S.S.
        • Kamoun W.S.
        • Farrar C.T.
        • Kirkpatrick N.D.
        • Niemeyer E.
        • de Graaf A.M.
        • et al.
        Angiopoietin-2 Interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.
        Clin Cancer Res. Jul 15 2010; 16 (Epub 2010 May 25): 3618-3627
        View in Article
        • Velikyan I.
        • Sundberg A.L.
        • Lindhe O.
        • Höglund A.U.
        • Eriksson O.
        • Werner E.
        • et al.
        Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
        J Nucl Med. Nov 2005; 46: 1881-1888
        View in Article
        • Pal A.
        • Glekas A.
        • Doubrovin M.
        • Balatoni J.
        • Namavari M.
        • Beresten T.
        • et al.
        Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
        Mol Imaging Biol. Sep-Oct 2006; 8: 262-277
        View in Article
        • Abourbeh G.
        • Dissoki S.
        • Jacobson O.
        • Litchi A.
        • Ben Daniel R.
        • Laki D.
        • et al.
        Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
        Nucl Med Biol. Jan 2007; 34: 55-70
        View in Article
        • Wang H.
        • Yu J.M.
        • Song X.R.
        • Yang G.R.
        • Mu D.B.
        • Zhao S.Q.
        • et al.
        Molecular imaging of epidermal growth factor receptor in glioma-bearing rats.
        Zhonghua Zhong Liu Za Zhi. May 2008; 30: 343-346
        View in Article
        • Lee F.T.
        • O'Keefe G.J.
        • Gan H.K.
        • Mountain A.J.
        • Jones G.R.
        • Saunder T.H.
        • et al.
        Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.
        J Nucl Med. Jun 2010; 51 (Epub 2010 May 19): 967-972
        View in Article

      Article info

      Publication history

      Published online: August 26, 2010
      Accepted: July 27, 2010
      Received in revised form: July 23, 2010
      Received: June 2, 2010

      Identification

      DOI: https://doi.org/10.1016/j.jns.2010.07.024

      Copyright

      © 2010 Elsevier B.V. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX